Ibrutinib may increase risk of hypertension

Call for more collaboration between oncologists and cardiologists
Reuters Health Staff writer
Blood pressure monitor reading high

Initiation of ibrutinib therapy is associated with an increased risk of hypertension and subsequent cardiovascular events, a study suggests.

US researchers evaluated the incidence of new or worsening hypertension and major adverse cardiovascular events in 562 consecutive patients treated with ibrutinib for lymphoid malignancies during 2009-2016.